&w=3840&q=100)
How China's new hybrid AI chip could rewrite the rules of global computing
The new chip merges conventional binary logic with stochastic, or probabilistic, logic to offer an alternative method for data processing. Importantly, the chip avoids reliance on US-restricted components.
What problem is China trying to solve with hybrid computing?
The report outlines two major limitations of conventional chips: the power wall and the architecture wall.
- The power wall stems from binary logic's high energy demands. While binary systems—built on 1s and 0s—offer high accuracy, they consume large amounts of power, making it hard to scale.
- The architecture wall refers to how alternative or non-silicon chips often cannot integrate well with the existing CMOS (complementary metal-oxide-semiconductor) infrastructure, which underpins most global computing today.
Hybrid computing, says Li's team, provides a way around both.
What is hybrid stochastic computing, and how does it work?
Binary systems rely on precise calculations, demanding heavy hardware resources. Probabilistic or stochastic computing, on the other hand, represents values through voltage signal frequencies, thus consuming less power but often introducing delays and imprecision.
By merging these two, Li's team created the Hybrid Stochastic Number system, combining:
> Binary numbers (accurate but power-hungry)
> Stochastic numbers (power-efficient but slower)
> A hybrid form that achieves low energy use with high computational reliability
The result, according to the team, is a chip that is more fault-tolerant, energy-efficient and resistant to signal noise.
Where is this technology being used?
According to the report, the chip has already been implemented in various real-world systems. In touch display systems, it improves user interaction by filtering out noise and detecting weak signals more accurately. In medical or industrial displays, it enables fast, low-power data processing for accurate readings.
It is also being used in flight control systems, where it delivers steady navigation and strong fault tolerance—crucial for aerospace and defence operations.
These systems benefit from the chip's in-memory computing capability, which cuts down energy-hungry data transfer between memory and processors, a major bottleneck in traditional systems.
How was the chip built despite US tech restrictions?
Despite the global race for cutting-edge chips being dominated by advanced nodes like 5nm or 3nm, Li's team used 110nm and 28nm manufacturing processes provided by Semiconductor Manufacturing International Corporation (SMIC), China's leading chipmaker.
This is significant. By relying on mature, domestically available technologies, the team effectively sidesteps US export restrictions on high-end semiconductors while still pushing the envelope on performance through architectural innovation, not brute force hardware.
What's next for this chip technology?
The team is now developing a custom instruction set architecture (ISA) and microarchitecture tailored for hybrid probabilistic computing, the report said. This will enable the chip to support more advanced applications, including AI model acceleration, speech and image recognition, and neural networks.
In essence, this could give China a home-grown pathway to support the future of large-scale AI and machine learning, independent of foreign technologies.
As the US-China tech rivalry deepens, Beijing is pursuing self-reliance in semiconductors and this chip could be a template for how to innovate around restrictions. Instead of trying to match the US in advanced lithography, China is redefining computing logic itself.
If successful, this approach could reshape global thinking about how chips are built, moving from raw transistor counts to new ways of doing math on silicon.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
4 hours ago
- Time of India
India narrows mobile internet speed gap with US, China
India, the largest data consumer globally, ranks 26th in average internet connection speed and is narrowing the gap with other major markets, data from US-based speed test company Ookla showed. Ookla's data showed India had a median download speed of 136.53 Mbps in the April to June period, having moved up 93 spots from No. 119 in September 2022, driven by rapidly expanding 5G coverage. In comparison, the US ranked 13th and China 8th, with median download speeds of 176.75 Mbps and 207.98 Mbps, respectively. According to the Ericsson Mobility Report , the per capita data consumption in India is the world's highest at 32 GB per month. It is 29 GB in China and 22 GB in the US. 'India witnessed a landmark transformation in its digital connectivity with the commercial launch of 5G in October 2022, propelling one of the world's fastest nationwide 5G network expansions,' said Affandy Johan, industry analyst, Ookla. 'This launch had a dramatic influence on download speeds across the country.' According to EY, 5G towers already account for about 57% of the total telecom towers in India. It said the country's 5G subscriber base reached 326 million at the end of March, accounting for some 28% of the total wireless connections. At the end of December 2024, India's average monthly 5G data usage per user stood at 40 GB, almost 1.5 times the average mobile data consumption. Industry experts said telecom companies in India spent nearly Rs 1.40 lakh crore in capital expenditure on 5G between FY23 and FY25, according to industry estimates. Vodafone Idea attributed the growth in both quality and quantity of telecom consumption in India to several factors, including low cost of data, rapid penetration of affordable smartphones, and sustained, large-scale investments by telecom operators in expanding both capacity and coverage. Reliance Jio and Bharti Airtel did not respond to ET's queries. ?Indian telcos have a fine record of always putting consumer affordability on priority despite at times that not being commensurate with their own cost to serve or produce,' said Sandip Das, a telecom veteran who has headed Reliance Jio and Hutchison Essar (now Vodafone Idea). 'This has led to largescale adoption and the fastest scale up to over a billion users.' Prashant Singhal, TMT emerging markets leader at EY Global said telecom operators need to balance revenue with network investments. 'Introducing tiered 5G pricing plans customised for different customer segments (e.g., heavy data users and gamers paying a premium) or for the matter content bundling with 5G plans would go a long way in enhancing customer value proposition,' Singhal said. Vinish Bawa, partner and leader, telecom, at PwC India, said that to sustain the pace of 5G expansion, telcos in India need to sharpen focus on rural coverage and plug indoor coverage gaps, besides investment in edge and cloud infrastructure to prepare for the AI-native future, while the government needs to ensure faster clearances for infrastructure deployment. Digital acceleration India's 600 million-strong smartphone base has also caused a big shift in digital acceleration. For instance, in 2024, Indians spent 4.9 hours per day on phone apps, a 3.1% growth over 2023, said EY, adding that in aggregate, India spent more than 1.1 trillion hours on digital platforms, higher than any other market worldwide. Meanwhile, subscription-based video of demand (SVOD) services increased five times in 2024 as compared with 2019, according to data from EY. India's digital payment ecosystem is also riding on greater smartphone penetration. Some 460 million people and 65 million merchants are using the Unified Payments Interface (UPI).
&w=3840&q=100)

Business Standard
5 hours ago
- Business Standard
Can mobile PLI scheme's winning model be replicated across other sectors?
An agile government-private partnership has proved a win-win for the mobile PLI scheme Surajeet Das Gupta New Delhi Listen to This Article Just two months after Prime Minister Narendra Modi returned to power with a thumping majority in May 2019 for a second time, Nripendra Misra, then the principal secretary to the PM, set up a committee to evaluate India's potential to 'become a manufacturing hub' for mobile devices. The timing was opportune. American President Donald Trump, then in his first term, had already unleashed a US-China tariff war. Multinationals from China — the world's largest manufacturing hub — were looking for alternative manufacturing destinations to find their way around the China Plus One strategy. Meanwhile, companies like Apple Inc had started


Mint
5 hours ago
- Mint
Sacrifices, trade-offs behind big win, says Glenmark's Saldanha
The road to drug discovery is long, arduous and littered with failure, but the payoff at the end makes it worth the trouble. It's a lesson that India's best pharmaceutical entrepreneurs knew all along. Yet, it took a Glenn Saldanha to prove it. 'We were always resilient in how we approached innovation. I think that's what finally rewarded us," Saldanha, chief executive officer and managing director of Glenmark Pharmaceuticals Ltd, told Mint in an exclusive interview. He was referring to one of the largest deals for an Indian biopharma firm after Glenmark's US-based unit Ichnos Glenmark Innovation (IGI) secured a $700-million exclusive licensing agreement with AbbVie for its blood cancer drug candidate last week. AbbVie will also pay as much as $1.23 billion as various milestones are completed, as well as tiered, double-digit royalties on net sales. ISB 2001, the investigational drug to treat multiple myeloma, is in phase-1 clinical trials and has shown promising data. In a trial with 35 patients who had exhausted all existing lines of therapy unsuccessfully, 79% showed a clinical response to it, and 30% were cancer-free. 'I hope this acts as a catalyst to expanding the innovation landscape in India…we've demonstrated that you can do it," said Saldanha. Last bet ISB 2001, developed on IGI's proprietary BEAT platform, was the firm's last bet. 'There was no plan B," said Saldanha. 'This was pretty much the end of the road. At this point, the technology had to demonstrate that it worked…or we don't know what we would have done as the next thing." The drug had been in discovery over the last five years, while the company had been working on the BEAT platform for about a decade. There were three other assets that the company stopped developing. ISB 2001 has received both the US FDA Orphan Drug and Fast Track designations, highlighting its Orphan Drug designation is given to drugs treating rare diseases, while a fast track designation intends to expedite the development and review of drugs for treating serious conditions and fill unmet medical needs. Following the licensing agreement, AbbVie will take over further development for phase-2 and phase-3 trials before it can file for regulatory approval. The process would typically take four to five years. The market size for multiple myeloma is estimated to grow to $50 billion by 2030. Should the drug hit the markets in 2030, taking into account the tiered double-digit royalties, Glenmark stands to earn an additional $2.02 billion in royalties until 2041, according to research by brokerage Nuvama. The deal validates several aspects of Glenmark, including the strength of IGI's BEAT platform, the potential for ISB 2001 to treat relapsed/refractory multiple myeloma, and its commercial viability following successful clinical trials, said an 11 July note by Motilal Oswal analysts. 'Moreover, AbbVie has established itself as a diversified biopharma leader, combining scientific innovation with strong commercial execution. In oncology, the company has built a robust presence anchored by two cornerstone therapies: Imbruvica, a BTK inhibitor, and Venclexta, a BCL-2 inhibitor. These medicines have transformed the treatment landscape for chronic lymphocytic leukemia and other B-cell malignancies, generating multi-billion-dollar revenues and reinforcing AbbVie's reputation as a pioneer in hematologic cancer," the note added. Huge sacrifices, trade-offs Saldanha has bet on innovation since he took the reins of the company in the late 90s. A few years after Glenmark was listed in 2000, it established its first R&D centre for novel biologics research in Switzerland. Over the years, the company did a number of licensing deals with novel assets. In 2019, it spun off its R&D entity under a new company, Ichnos Sciences, which built on its proprietary BEAT bispecific platform. The two announced the creation of Ichnos Glenmark Innovation (IGI) in 2024. The company's focus on innovation created a lot of frustration for investors and stakeholders, Saldanha said. '[We were] bordering on being called eccentric," he said. The company also had to sell its stake in its active pharmaceutical ingredient (API) division, Glenmark Life Sciences, to pare its debt in 2023, which was approximately ₹4,500-4,600 crore. Glenmark sold 75% stake in the unit to industrial conglomerate Nirma for ₹5,650 crore. The company has made 'huge sacrifices, huge trade-offs," said Saldanha. With the GLS sale, the company had a choice to decide 'which end of the value chain we play", said Saldanha. 'Whether we play on this API stable end of the value chain, and generate revenues like that, or we play on the high end of the value chain, which is innovation." But innovation is not a cost game, he said. 'It's all about being able to understand where the therapy is going and how to come up with solutions." What's next for Glenmark? IGI spends about $70 million annually on new drug research. With the upfront payment it receives, it will be self-funded for the next three to four years, said Saldanha. The company will also look at rewarding shareholders with dividends. Apart from that, there are no immediate investment plans, said Saldanha. 'At least for the next year or two, we won't do anything. We'll just continue regrouping and trying to figure out strategically where we can further add value," he said. The deal is a big event for the company, which 'basically resets the whole agenda for the company", he said. 'We have to really reset and rethink how we want to see the company over the next five to ten years." ISB 2001's early success has validated the BEAT platform. 'We think we've now got it right with the technology…the idea is how can we exploit that technology much more effectively to add more products and do more," said Saldanha. The unit has another asset called ISB 2301, which is in late pre-clinical development and will go to the clinic next year. This drug will target solid tumours, said Saldanha. IGI also has a couple of other early-stage programs. '...over the next three, four years, we will exploit the technology as effectively as possible."